Physician profile
Devinda Desoyza
NPI 1710972435
$797.25
in general payments reported to CMS, 2019-2025
14 companies · $90.21 in 2025
The $90.21 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.61 · 2022: $323 · 2023: $290 · 2024: $24.61 · 2025: $90.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.46 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $197.32 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $158.10 | 2022-2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $74.97 | 2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $69.30 | 2022-2025 | Velphoro |
| Baxter Healthcare | $46.27 | 2022 | |
| Glaxosmithkline, LLC. | $40.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.84 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $35.30 | 2022 | |
| Mallinckrodt Hospital Products INC. | $30.61 | 2023 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $26.13 | 2023 | |
| Amgen INC. | $24.95 | 2021 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2023 | Farxiga |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinda Desoyza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.